Cancer and Immune System: Basic Concepts and Targets for Intervention

Seminars in Oncology

Volumn 42, Issue 4, 2015, Pages 523-538

  Pardoll, Drew ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CHROMATIN STRUCTURE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA DAMAGE; DNA METHYLATION; HUMAN; IMMUNE EVASION; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOCYTE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

CANCER VACCINE;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS;

EID: 84940379785     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.05.003     Document Type: Review

References (114)

1. R.W. Baldwin Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of implanted tumours Br J Cancer 9 1955 652 657
2. R.T. Prehn, and J.M. Main Immunity to methylcholanthrene-induced sarcomas J Natl Cancer Inst 18 1957 769 778
3. F. Ciardiello, R. Bianco, V. Damiano, and et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 Clin Cancer Res 5 1999 909 916
4. D.J. Slamon, B. Leyland-Jones, S. Shak, and et al. Use of chemorapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
5. E.R. Fearon, and B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
6. T. Sjoblom, S. Jones, L.D. Wood, and et al. consensus coding sequences of human breast and colorectal cancers Science 314 2006 268 274
7. P.F. Robbins, Y.C. Lu, M. El-Gamil, and et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells Nat Med 19 6 2013 747 752
8. P. Kvistborg, D. Philips, S. Kelderman, and et al. Anti-CTLA-4 rapy broadens melanoma-reactive CD8+T cell response Sci Transl Med 6 2014 254
9. S.I. Abrams, S.N. Khleif, E.S. Bergmann-Leitner, and et al. Generation of stable CD4+and CD8+T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations Cell Immunol 182 1997 137 151
10. P.A. Jones, and S.B. Baylin epigenomics of cancer Cell 128 2007 683 692
11. P. Van Der Bruggen, Y. Zhang, P. Chaux, and et al. Tumor-specific shared antigenic peptides recognized by human T cells Immunol Rev 188 2002 51 64
12. Y. Kawakami, P.F. Robbins, R.F. Wang, and et al. use of melanosomal proteins in immunorapy of melanoma J Immunor 21 1998 237 246
13. F.M. Burnet concept of immunological surveillance Prog Exp Tumor Res 13 1970 1 27
14. J. Rygaard, and C.O. Povlsen nude mouse vs. Hyposis of immunological surveillance Transplant Rev 28 1976 43 61
15. G. Gaidano, and R. Dalla-Favera Biologic aspects of human immunodeficiency virus-related lymphoma Curr Opin Oncol 4 1992 900 906
16. E.A. Mesri, E. Cesarman, L. Arvanitakis, and et al. Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells J Exp Med 183 1996 2385 2390
17. M. Boshart, L. Gissmann, H. Ikenberg, and et al. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer EMBO J 3 1984 1151 1157
18. S. Euvrard, J. Kanitakis, C. Pouteil-Noble, and et al. Skin cancers in organ transplant recipients Ann Transplant 2 1997 28 32
19. G.P. Dunn, C.M. Koebel, and R.D. Schreiber Interferons, immunity and cancer immunoediting Nat Rev Immunol 6 2006 836 848
20. V. Shankaran, H. Ikeda, A.T. Bruce, and et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 2001 1107 1111
21. K. Staveley-O'Carroll, E. Sotomayor, J. Montgomery, and et al. Induction of antigen-specific T cell anergy: An early event in course of tumor progression Proc Natl Acad Sci U S A 95 1998 1178 1183
22. D. Getnet, C.H. Maris, E.L. Hipkiss, and et al. Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells J Immunol 182 2009 4675 4685
23. C.G. Drake, E. Jaffee, and D.M. Pardoll Mechanisms of immune evasion by tumors Adv Immunol 90 2006 51 81
24. B. Bogen Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma Eur J Immunol 26 1996 2671 2679
25. K. Staveley-O'Carroll, E. Sotomayor, J. Montgomery, and et al. Induction of antigen-specific T cell anergy: An early event in course of tumor progression Proc Natl Acad Sci U S A 95 1998 1178 1183
26. C.G. Drake, A.D. Doody, M.A. Mihalyo, and et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen Cancer Cell 7 2005 239 249
27. G. Willimsky, and T. Blankenstein Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance Nature 437 7055 2005 141 146
28. L.T. Nguyen, A.R. Elford, K. Murakami, and et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance J Exp Med 195 2002 423 435
29. A.L. Cox, J. Skipper, Y. Chen, and et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines Science 264 5159 1994 716 719
30. S. Sakaguchi, M. Ono, R. Setoguchi, and et al. Foxp3+CD25+CD4+natural regulatory T cells in dominant self-tolerance and autoimmune disease Immunol Rev 212 2006 8 27
31. T.J. Curiel, G. Coukos, L. Zou, and et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942 949
32. U.K. Liyanage, T.T. Moore, H.G. Joo, and et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma J Immunol 169 2002 2756 2761
33. R.P. Sutmuller, L.M. van Duivenvoorde, A. van Elsas, and et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor rapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses J Exp Med 194 2001 823 832
34. A.M. Ercolini, B.H. Ladle, E.A. Manning, and et al. Recruitment of latent pools of high-avidity CD8(+) T cells to antitumor immune response J Exp Med 201 2005 1591 1602
35. H. Yu, D. Pardoll, and R. Jove STATs in cancer inflammation and immunity: A leading role for STAT3 Nat Rev Cancer 9 11 2009 798 809
36. C.L. Yu, D.J. Meyer, G.S. Campbell, A.C. Larner, and et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by Src oncoprotein Science 269 5220 1995 81 83
37. H. Yu, M. Kortylewski, and D. Pardoll Crosstalk between cancer and immune cells: role of STAT3 in tumour microenvironment Nat Rev Immunol 7 1 2007 41 51
38. T. Wang, G. Niu, M. Kortylewski, and et al. Regulation of innate and adaptive immune responses by Stat-3 signaling in tumor cells Nat Med 10 1 2004 48 54
39. M. Kortylewski, M. Kujawski, T. Wang, and et al. Inhibiting Stat3 signaling in hematopoietic system elicits multicomponent antitumor immunity Nat Med 11 12 2005 1314 1321
40. M. Kortylewski, H. Xin, M. Kujawski, and et al. Regulation of IL-23 and IL-12 balance by Stat3 signaling in tumor microenvironment Cancer Cell 15 2 2009 114 123
41. S. Wu, K.J. Rhee, E. Albesiano, and et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses Nat Med 15 9 2009 1016 1022
42. M. Tosolini, A. Kirilovsky, B. Mlecnik, and et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer Cancer Res 71 4 2011 1263 1271
43. S. Kusmartsev, and D.I. Gabrilovich Role of immature myeloid cells in mechanisms of immune evasion in cancer Cancer Immunol Immunor 55 2006 237 245
44. M.R. Young, G.J. Petruzzelli, K. Kolesiak, and et al. Human squamous cell carcinomas of head and neck chemoattract immune suppressive CD34(+) progenitor cells Hum Immunol 62 2001 332 341
45. V. Bronte, E. Apolloni, A. Cabrelle, and et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells Blood 96 2000 3838 3846
46. V. Bronte, P. Serafini, C. De Santo, and et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice J Immunol 170 2003 270 278
47. A. Mazzoni, V. Bronte, A. Visintin, and et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism J Immunol 168 2002 689 695
48. A.H. Zea, P.C. Rodriguez, M.B. Atkins, and et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion Cancer Res 65 2005 3044 3048
49. S. Nagaraj, and D.I. Gabrilovich Myeloid-derived suppressor cells in human cancer Cancer J 4 2010 348 353
50. D.I. Gabrilovich, S. Ostrand-Rosenberg, and V. Bronte Coordinated regulation of myeloid cells by tumours Nat Rev Immunol 12 2012 253 268
51. J. Schmielau, and O.J. Finn Activated granulocytes and granulocyte-derived hydrogen peroxide are underlying mechanism of suppression of t-cell function in advanced cancer patients Cancer Res 61 2001 4756 4760
52. D.H. Munn, M.D. Sharma, J.R. Lee, and et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase Science 297 2002 1867 1870
53. B. Baban, A.M. Hansen, P.R. Chandler, and et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation Int Immunol 17 2005 909 919
54. A.L. Mellor, P. Chandler, B. Baban, and et al. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase Int Immunol 16 2004 1391 1401
55. D.H. Munn, M.D. Sharma, D. Hou, and et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes J Clin Invest 114 2004 280 290
56. G.C. Blobe, W.P. Schiemann, and H.F. Lodish Role of transforming growth factor beta in human disease N Engl J Med 342 2000 1350 1358
57. J.J. Letterio, and A.B. Roberts Regulation of immune responses by TGF-beta Annu Rev Immunol 16 1998 137 161
58. L. Gorelik, and R.A. Flavell Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease Immunity 12 2000 171 181
59. M.L. Chen, M.J. Pittet, L. Gorelik, and et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo Proc Natl Acad Sci U S A 102 2005 419 424
60. N.W. Palm, and R. Medzhitov Pattern recognition receptors and control of adaptive immunity Immunol Rev 227 1 2009 221 233
61. T. Kawai, and S. Akira Toll-like receptors and ir crosstalk with or innate receptors in infection and immunity Immunity 34 5 2011 637 650
62. A. Poltorak, X. He, I. Smirnova, and et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene Science 82 5396 1998 2085 2088
63. L. Apetoh, F. Ghiringhelli, A. Tesniere, and et al. Toll-like receptor 4-dependent contribution of immune system to anticancer chemorapy and radiorapy Nat Med 13 9 2007 1050 1059
64. S. Reikine, J.B. Nguyen, and Y. Modis Pattern recognition and signaling mechanisms of RIG-I and MDA5 Front Immunol 5 2014 342
65. J.J. Woodward, A.T. Iavarone, and D.A. Portnoy c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response Science 328 5986 2010 1703 1705
66. D.L. Burdette, and R.E. Vance STING and innate immune response to nucleic acids in cytosol Nat Immunol 14 1 2013 19 26
67. J. Wu, and Z.J. Chen Innate immune sensing and signaling of cytosolic nucleic acids Annu Rev Immunol 32 2014 461 488
68. J. Fu, I.J. Malm, D.K. Kadayakkara, H. Levitsky, and et al. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors Cancer Res 74 2014 4042 4052
69. J. Fu, D.B. Kanne, M. Leong, and et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade Sci Transl Med 7 2015 283
70. D.J. Lenschow, T.L. Walunas, and J.A. Bluestone CD28/B7 system of T cell costimulation Annu Rev Immunol 14 1996 233 258
71. M. Azuma, D. Ito, H. Yagita, and et al. B70 antigen is a second ligand for CTLA-4 and CD28 Nature 366 1993 76 79
72. G.J. Freeman, J.G. Gribben, V.A. Boussiotis, and et al. Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation Science 262 1993 909 911
73. K.S. Hathcock, G. Laszlo, H.B. Dickler, and et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation Science 262 1993 905 907
74. P.S. Linsley, W. Brady, M. Urnes, and et al. CTLA-4 is a second receptor for B cell activation antigen B7 J Exp Med 174 1991 561 569
75. H. Schneider, J. Downey, A. Smith, and et al. Reversal of TCR stop signal by CTLA-4 Science 313 2006 1972 1975
76. H. Schneider, X. Smith, H. Liu, G. Bismuth, and C.E. Rudd CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization Eur J Immunol 38 2008 40 47
77. O.S. Qureshi, Y. Zheng, K. Nakamura, and et al. Trans-endocytosis of CD80 and CD86: A molecular basis for cell-extrinsic function of CTLA-4 Science 332 2011 600 603
78. E.A. Tivol, F. Borriello, A.N. Schweitzer, and et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 1995 541 547
79. P. Waterhouse, J.M. Penninger, E. Timms, and et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 Science 270 1995 985 988
80. K. Wing, Y. Onishi, P. Prieto-Martin, and et al. CTLA-4 control over Foxp3+regulatory T cell function Science 322 2008 271 275
81. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
82. H. Dong, S.E. Strome, D.R. Salomao, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion Nat Med 8 2002 793 800
83. Taube JM AR, Xu H, Sharma R, et al. B7-H1 expression co-localizes with inflammatory infiltrates in benign and malignant melanocytic lesions: Implications for immunorapy. Sci Translat Med. 28;4:127ra37.
84. B.T. Fife, K.E. Pauken, T.N. Eagar, and et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking TCR-induced stop signal Nat Immunol 10 2009 1185 1192
85. L.M. Francisco, V.H. Salinas, K.E. Brown, and et al. PD-L1 regulates development, maintenance, and function of induced regulatory T cells J Exp Med 206 2009 3015 3029
86. H. Dong, G. Zhu, K. Tamada, and et al. B7-H1, a third member of B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1999 1365 1369
87. Y. Latchman, C.R. Wood, T. Chernova, and et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 2001 261 268
88. S.Y. Tseng, M. Otsuji, K. Gorski, and et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells J Exp Med 193 2001 839 846
89. M.J. Butte, M.E. Keir, T.B. Phamduy, and et al. Programmed death-1 ligand 1 interacts specifically with B7-1 costimulatory molecule to inhibit T cell responses Immunity 27 2007 111 122
90. D.L. Barber, E.J. Wherry, D. Masopust, and et al. Restoring function in exhausted CD8 T cells during chronic viral infection Nature 439 2006 682 687
91. A. Gros, P.F. Robbins, X. Yao, and et al. PD-1 identifies patient-specific CD8 tumor-reactive repertoire infiltrating human tumors J Clin Invest 124 2014 2246 2259
92. M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, and et al. Tumor antigen-specific CD8 T cells infiltrating tumor express high levels of PD-1 and are functionally impaired Blood 114 2009 1537 1544
93. S.L. Topalian Topalian, C.G. Drake, and D.M. Pardoll Immune checkpoint blockade: A common denominator approach to cancer rapy Cancer Cell 27 2015 450 461
94. R.H. Thompson, M.D. Gillett, J.C. Cheville, and et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential rapeutic target Proc Natl Acad Sci U S A 101 2004 17174 17179
95. C. Steidl, S.P. Shah, B.W. Woolcock, and et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers Nature 471 2011 377 381
96. A.T. Parsa, J.S. Waldron, A. Panner, and et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat Med 13 2007 84 88
97. M. Marzec, Q. Zhang, A. Goradia, and et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) Proc Natl Acad Sci U S A 105 2008 20852 20857
98. T.F. Gajewski, J. Louahed, and V.G. Brichard Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunorapy Cancer J 16 2010 399 403
99. J.R. Brahmer, C.G. Drake, I. Wollner, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
100. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
101. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
102. K.H. Yi, and L. Chen Fine tuning immune response through B7-H3 and B7-H4 Immunol Rev 229 2009 145 151
103. C. He, H. Qiao, H. Jiang, and et al. inhibitory role of b7-h4 in antitumor immunity: Association with cancer progression and survival Clin Dev Immunol 2011 695834
104. J.F. Grosso, C.C. Kelleher, T.J. Harris, and et al. LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems J Clin Invest 117 2007 3383 3392
105. S.D. Blackburn, H. Shin, W.N. Haining, and et al. Coregulation of CD8+T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 10 2009 29 37
106. J.F. Grosso, M.V. Goldberg, D. Getnet, and et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells J Immunol 182 2009 6659 6669
107. S.R. Woo, M.E. Turnis, M.V. Goldberg, and et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res 72 2012 917 927
108. C. Zhu, A.C. Anderson, A. Schubart, and et al. Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity Nat Immunol 6 2005 1245 1252
109. S.F. Ngiow, B. von Scheidt, H. Akiba, and et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors Cancer Res 71 2011 3540 3551
110. J. Fourcade Fourcade, Z. Sun, and et al. PD-1 and Tim-3 regulate expansion of tumor antigen-specific CD8 T cells induced by melanoma vaccines Cancer Res 74 4 2014 1045 1055
111. K. Sakuishi, L. Apetoh, J.M. Sullivan, and et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity J Exp Med 207 2010 2187 2194
112. P.E. Zarek, C.T. Huang, E.R. Lutz, and et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and generation of adaptive regulatory T cells Blood 111 2008 251 259
113. S. Deaglio, K.M. Dwyer, W. Gao, and et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression J Exp Med 204 2007 1257 1265
114. A.T. Waickman, A. Alme, L. Senaldi, and et al. Enhancement of tumor immunorapy by deletion of A2A adenosine receptor Cancer Immunol Immunor 61 2012 917 926